The candidate proto-oncogene BCL3 was isolated through its involvement in the t(14;19) found in chronic lymphocytic leukemia and other B-cell neoplasms. As a member of the IkB family, BCL3 plays a role in the immune response by interactions with the NF-kB family of transcription factors. In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated ®ve lines of Em-BCL3 transgenic mice. Transgenic animals develop normally but show splenomegaly and an accumulation of mature B cells in lymph nodes, bone marrow and peritoneal cavity. A hyperresponsive immune system is suggested by the follicular hyperplasia and plasmacytosis in lymph nodes of unimmunized animals, increased incidence of antibodies to self-antigens, and a heightened response to crosslinking of surface IgM. Statistically signi®cant decreases in serum IgM and IgG3, but an increase in IgG1 and IgA were also observed. No lymphoid neoplasms have been identi®ed in transgenic animals. The expansion of B cells in vivo is consistent with the overexpression of BCL3 as being one step in the multi-step process of leukemogenesis. The phenotype also suggests that BCL3 plays a part in B cell proliferation and isotype switching.
Introduction
The t(14;19) translocation is a recurring chromosomal abnormality found in B-cell neoplasms, most commonly chronic lymphocytic leukemia (CLL) (Asou et al., 1993; Crossen et al., 1993; Ueshima et al., 1985) . This translocation juxtaposes the BCL3 gene to the immunoglobulin heavy chain locus and results in the overexpression of full-length BCL3 mRNA (Ohno et al., 1990) . Patients with this translocation appear to have a worse prognosis than those without, and their leukemia is prone to transform into a large cell lymphoma or the prolymphocytic variant of CLL, both of which are associated with shorter survival (McKeithan et al., 1997; Michaux et al., 1996 Michaux et al., , 1997 .
BCL3 is a member of the IkB family of proteins that regulate the Rel/NF-kB family of transcription factors (which includes RelA, RelB, c-Rel, p50, and p52) (Kerr et al., 1992) . Both Rel/NF-kB and IkB have been implicated in normal and malignant cell growth control, especially in cells of the immune system (Blank et al., 1992; Fracchiolla et al., 1993) . They regulate over 100 genes, including cytokines, growth factors, adhesion molecules, and proto-oncogenes. However, little is known concerning the target genes that may mediate the contribution of Rel/NF-kB to oncogenesis.
The IkB family includes at least ®ve dierent members: IkBa, IkBb, IkBg, IkBe, and BCL3. The various IkB proteins have distinct speci®cities for interactions with Rel/NF-kB complexes but in most cases act to inhibit transcription by NF-kB. The best delineated example is that of IkBa and NF-kB. In this case NF-kB is retained in the cytoplasm by IkBa. IkBa binds to the Rel homology domain of NF-kB and masks its nuclear localization signals, thereby preventing the movement of NF-kB into the nucleus (Baeuerle and Baltimore, 1988) . Upon stimulation, IkBa is phosphorylated, ubiquitinated and degraded, allowing NF-kB to translocate to the nucleus.
BCL3 is thought to function dierently and has been shown to act as an antirepressor or coactivator at kB sites. BCL3 is a nuclear protein (Zhang et al., 1994) that speci®cally interacts with homodimers of p50 or p52 (Franzoso et al., 1992; Hatada et al., 1992; Kerr et al., 1992; Wulczyn et al., 1992) , which are found in the nucleus of resting cells. p50 and p52 have no de®ned transactivating domains, and as homodimers they may act competitively to inhibit binding to consensus DNAbinding (kB) sites by NF-kB heterodimers that can transactivate. It has been proposed that BCL3 binding in vivo may remove these competing, non-transactivating dimers from kB sites, thereby providing an antirepressor eect (Franzoso et al., 1992) . Others, using reporter gene transfection assays in mammalian cells, have demonstrated that BCL3 can directly transactivate kB sites in association with p50 or p52 homodimers (Bours et al., 1993; Fujita et al., 1993) .
Recently, it has been shown for the P-selectin promoter, that coexpression of BCL3 with either p50 or p52 has dierential eects on reporter gene expression. Coexpression of BCL3 with p52 enhances the gene expression seen with p52 alone. Coexpression with p50, however, prevents the repression of promoter activity seen with p50 alone (Pan and McEver, 1995) . To date, this is the only promoter for which dierential eects of BCL3 have been shown, and whether BCL3 actually functions as an antirepressor or coactivator or both with other promoters is unclear. In any event, these results suggest that the overexpression of BCL3 leads to leukemogenesis through interactions with NF-kB members, ultimately resulting in the inappropriate or excessive expression of kB-dependent genes.
The physiologic function of BCL3 is unclear. Dierent groups have shown that it can function as an immediate early response gene in both T and B lymphocytes: stimulation of mixed lymphocyte populations by T or B cell speci®c mitogens results in a rapid induction of BCL3 message (Bhatia et al., 1991; Ohno et al., 1990) . Recently, studies of BCL3 knockout mice have shown that BCL3 is required for germinal center [GC] formation and for the production of antigenspeci®c antibodies (Franzoso et al., 1997; Schwarz et al., 1997) . Others have shown that the levels of expression in B cells may depend on developmental stage: cell lines of B cell malignancies corresponding to various stages of development show consistently higher levels of expression at the stage of the mature B cell (Bhatia et al., 1991) .
In order to study the role of BCL3 overexpression in lymphoid malignancies, we generated ®ve lines of Em-BCL3 transgenic mice, which expressed BCL3 in both T and B cells, and herein describe their phenotype.
Results

Generation of Em-BCL3 transgenic mice
Of 26 mice derived from microinjected zygotes, eight were identi®ed as transgenic by Southern analysis. Estimates of transgene copy number by Southern analysis varied from two to greater than 20. One of the founder mice died during parturition of unknown causes. Five founders were bred to establish lines. The frequency of transmission of the transgene among heterozygotes was compatible with a normal Mendelian autosomal transmission, and no increased embryonal lethality could be demonstrated. Transgene expression was shown by performing RT ± PCR with primers that spanned the intron. All lines showed expression of the expected 133 bp fragment in spleen. Expression was also found in thymus and lymph node.
Positive selection of splenic B cells con®rmed that, as expected, the transgene was expressed not only in T cells but also in B cells. This was determined by comparing the intensity of the 133 bp band of a 96% pure population of B cells with that of a population containing 62% of T cells and 10% of B cells. By doing so, it was apparent that the remaining 4% of T cells in the puri®ed population of B cells could not alone account for the intensity of the 133 bp band that was seen. To ensure that equivalent levels of RNA were compared, we included primers for the housekeeping gene Hprt in the same reactions, and compared reactions in which the intensity of this band were equivalent.
Em-BCL3 transgenic mice develop a lymphoproliferative disorder
Previous transgenic studies using similar constructs have helped determine the transforming ability of other proto-oncogenes involved in B cell malignancies including c-myc and BCL2. These studies have helped in the understanding of the oncogenic potential of these genes and the cellular eects of overexpression.
We have found that Em-BCL3 mice develop an accumulation of mature B cells. From the age of 5 weeks transgenic mice exhibit splenomegaly compared to sex-matched littermate controls (Figure 1 ). Of the ®rst 23 pairs or triplets examined (sacri®ced at various ages between 38 and 119 days) transgenics spleen weights were always heavier except in one instance (median=96 mg for transgenics, 77 mg for controls). Using a linear regression model predicting natural log spleen weight within litters, transgenic spleens are estimated to be 0.29 log mg larger than control spleens on average, corresponding to a 34% increase in spleen weight among transgenics (95% con®dence interval ranges from 17 ± 52% larger, P50.001 for testing hypothesis of no dierence). With respect to body weight, transgenic animals are estimated to be 1.04 g lighter than controls (95% con®dence intervals for transgenic minus control is 72.17 to 0.09), P=0.70 for testing hypothesis of no dierence).
There was little variation in spleen weight among controls (range 69 ± 133 mg), but transgenic mice exhibited a greater variation in spleen weight (range 82 ± 218 mg). No factors, including the age of the animal or founder line, were identi®ed that could account for the variation in splenomegaly among transgenic animals. In addition, the degree of splenomegaly appeared to correlate with the degree of enlargement observed in mesenteric lymph nodes.
Histologically, mesenteric and inguinal lymph nodes of control, littermate mice showed no evidence of lymphoid hyperplasia and contained no or only a few GC's and only rare plasma cells. In contrast, the majority of transgenic lymph nodes showed follicular hyperplasia, and a variable number of transgenic lymph nodes also showed plasma cell hyperplasia. The follicles were enlarged and increased in number, sheets (Figure 2c ± f) in greatly expanded medullary cords, which extended into the normal position of the cortex. In some instances, plasma cells were also noted in the subcapsular sinuses. These alterations in some instances were accompanied by a marked distortion of lymph node architecture, but not by gross eacement as typically seen in malignant proliferations. The plasma cells were mature with small eccentric nuclei with condensed chromatin and amphophilic cytoplasm with cytoplasmic hofs. Only a very small fraction of plasma cells showed cytoplasmic staining with antiIgM (Figure 2f ) whereas the great majority were positive, in varying intensities, with anti-IgG ( Figure  2e ).
Lymph nodes from a minority of transgenic mice were essentially indistinguishable from controls on standard hematoxylin and eosin-stained sections. Even in these instances, anti-B220 immunostains revealed an expanded B-cell area, which was found as well in the more obviously hyperplastic nodes (Figure 2a) .
The histological pattern in the spleen also varied. In many of the mice, the architectural pattern was not obviously dierent from control littermates, either in hematoxylin and eosin-stained sections or with anti-B220 or anti-IgG immunostains. In cases of splenomegaly, the relative expansion of the red and white pulp varied; some enlarged spleens showed follicular hyperplasia, but in others, the red pulp was preferentially expanded. In both controls and transgenics, hematopoiesis was prominent within the red pulp, but many transgenic spleens showed increased numbers of mature neutrophils.
Other tissues including thymus, skin, gastrointestinal tract, and liver were found to be normal by histological analysis. No systematic dierences in thymus weight were noted. So far Em-BCL3 transgenic mice have not demonstrated any dierence in survival compared to littermate controls, and founder mice have survived up to the age of 20 months. No lymphoid tumors have so far been seen in the mice, including 12 transgenic animals over a year in age.
Expression of a BCL3 transgene results in an accumulation of mature B cells and development of germinal centers
The t(14;19) is associated most frequently with CLL, but is also seen in de novo B-cell lymphomas of varying histological subtypes. The phenotype of CLL consists of a clonal accumulation of mature CD5-positive B cells in lymph node, bone marrow, and peripheral blood. We therefore examined transgenic animals in all of these lymphoid compartments including the peritoneal cavity.
Flow cytometry revealed an expansion in the population of mature B cells in the lymph nodes of transgenic animals. Among 18 pairs of transgenics and littermate controls examined, all except one showed a greater percentage of B220-positive cells in the transgenic animals ( Figure 3a ). These changes were observed in the ®ve dierent lines that were examined. Furthermore, there was a consistent threefold increase in the number of GC cells, as measured by PNA positivity, in transgenic lymph nodes (mean of 5 vs 15% for controls and transgenics respectively; ranges for two groups do not overlap, n=4 controls and ®ve transgenics) (Figure 3b ). In these studies the gates were chosen empirically in order to analyse separately the larger, activated lymphocytes. Gates that included primarily the smaller and presumably resting lymphocytes produced similar results in terms of an increased number of GC cells in transgenic lymph nodes. No dierences were noted in the expression of IgD, IgM, CD5, CD25/IL2Ra, CD80/B7-1, CD86/B7-2, or CD69 between transgenic and control B cells.
An increase in the proportion of mature B cells was again noted in transgenic bone marrow, as de®ned by the proportion of cells coexpressing IgM and IgD while using a gate for small lymphocytes, giving mean percentages of 77 vs 62% in seven transgenic mice and eight controls respectively (P50.001 for twosample t-test; ranges for the two groups do not overlap). This dierence may be due either to an alteration in maturation or to an increased number of recirculating mature peripheral B-cells.
Analysis of peritoneal lymphocytes re¯ected the changes seen elsewhere, namely an increase in the proportion of B cells. No changes were seen in the proportion of B1 B cells as a percentage of all peritoneal B cells. Complete blood counts and dierential counts were not obviously dierent between control and transgenic animals. Examination of Peyer's patches revealed no dierences in terms of the proportion of B220-positive cells, GC cells, or IgAexpressing B cells. No dierences were found between control and transgenic animals in the proportion of double negative, double positive, CD4+, and CD8+ cells in the thymus or in the CD4+/CD8+ ratio in spleen and lymph node.
Thus, Em-BCL3 animals develop a lymphoproliferative disorder consisting of a generalized accumulation of mature B cells, and provide a useful model for studying the synergistic role of other genetic events required for transformation in B cell malignancies.
Em-BCL3 B cells demonstrate increased proliferation and upregulation of CD86 to BCR cross-linking
Cellular mechanisms that can account for an in vivo expansion of the lymphocyte population include increased proliferation or increased resistance to apoptosis. We therefore examined Em-BCL3 lymphocytes in vitro using proliferation and survival assays.
Spleen cells from transgenic mice demonstrated a moderate increase in proliferation to membrane IgM ligation with F(ab') 2 goat anti-murine m. Using a linear regression model of log(thymidine incorporation), including an eect of day of analysis and type of animal (six transgenics vs six controls), transgenic splenocytes at 48 h and 72 h showed 141 and 175% of the incorporation found in controls (P=0.04 and 0.016, respectively). These dierences were seen using whole spleen preparations but not when using cultures depleted of T cells. No consistent dierences were seen when using lipopolysaccharide [LPS] as a mitogen. In initial experiments, analysis of the cell surface markers CD25/IL2Ra, CD80, CD86, CTLA4, or CD69 did not reveal any dierences in upregulation over 72 h between control and transgenic splenic B cells after LPS treatment.
However, there was an increased sensitivity to B-cell receptor [BCR] ligation by F(ab') 2 anti-IgM as judged BCL3 transgenic mice develop a lymphoproliferative disorder S Tiong Ong et al by up-regulation of the costimulatory molecule CD86 at 24 h (Figure 4 ). These dierences were most apparent using concentrations of F(ab') 2 at 1.5 mg/ml, in which case the percentage of CD86-positive B cells was 1.6 times that in control animals (mean: 52 vs 81% in control and transgenics respectively, with no overlap, n=4 controls and four transgenics). In addition, at this anti-m concentration the mean CD86 uorescence of the positive cells was also increased by 1.4-fold. At 5 mg/ml of F(ab') 2 a smaller dierence in the percentage of CD86 positive cells B220 cells were observed, but there was again an increase in the mean uorescence of the positive cells by 1.3-fold. Expression of CD86 in unstimulated B cells was not increased above that of control animals.
Using a 7-amino-actinomycin D [7-AAD] exclusion assay we were unable to show any consistent dierences in survival between control and transgenic B cells or T cells. In addition, no dierences to either dexamethasone or anti-m mediated apoptosis were seen (data not shown). Together these results suggest that B cell accumulation results from increased proliferation, rather than a defect in apoptosis, and that this may be mediated by an enhanced response to BCR crosslinking.
Unimmunized Em-BCL3 mice produce lower levels of IgM but have increased levels of IgG1 and IgA
The NF-kB/Rel transcription factors have been implicated in Ig class switching by studies using B cells from p50/NF-kB knockout mice. To determine whether BCL3 has a similar role, we measured basal production of antibodies in unimmunized transgenic and control littermates. Resting immunoglobulin levels were signi®cantly dierent for several isotypes. In transgenic animals, the geometric mean concentrations of IgM and IgG3 were 42 and 61% of control values (P50.001 and P=0.006, respectively). In contrast, mean concentrations for IgG1 and IgA in transgenic sera were 137 and 228% of the means in controls (P=0.033 and 050.001, respectively) ( Figure 5 ). No signi®cant dierences were found in IgE (not shown), IgG2a or IgG2b levels in this limited number of animals. These results further con®rm the importance of NF-kB/Rel family members in antibody production and isotype switching.
Em-BCL3 animals develop anti-dsDNA antibodies
Although the transgenic animals showed no evidence of any organ-speci®c autoimmume disease we noted that they produced detectable serum titers of IgG2a to dsDNA as measured by ELISA. Pooled positive control sera were obtained from SNF1 mice. Four of 18 transgenic mice and one out of 17 controls had titers above the positive controls. The median titers for the control and transgenic mice were 0.18 and 0.25 respectively (the median value for the transgenic mice is nearly equal to the 75th percentile of the control group). Wilcoxon's rank-sum test yields a P-value of 0.112 for testing the null hypothesis that the underlying distributions are equivalent. Although this P-value is not signi®cant by conventional standards, the data are suggestive of a dierence between the two groups (see x-axis of Figure 6 ). Finally, there was a positive correlation of 0.54 between log spleen weight and log IgG2a titer for transgenic animals (P=0.020), but a negative correlation of 70.35 for controls (P=0.18), Figure 4 A representative histogram plot of splenocytes cultured with 0.15 mg/ml F(ab') 2 goat anti-murine m for 24 h and stained for CD86 (B7-2) and B220. CD86 expression is shown for a control and transgenic littermate pair. The percentage of cells expressing high levels of CD86, de®ned as those within the bar, was higher in the transgenic animal in all four pairs of littermates tested, by a factor of 1.6 (mean values of 52 vs 81%, among transgenics and controls respectively). The mean¯uorescence of the cells within the bar was increased by a factor of 1.4 Figure 5 Resting antibody production. Concentrations obtained by ELISA from control animals (open squares) and transgenic animals (closed diamonds) are plotted for each speci®c isotype. Except for IgM, values were analysed on two separate days and plotted together after correction for the eect of day of analysis. Reanalysis of a subset of samples con®rmed the accuracy of this correction BCL3 transgenic mice develop a lymphoproliferative disorder S Tiong Ong et al though the latter value was due primarily to a single outlying observation ( Figure 6 ).
Discussion
Em-BCL3 transgenic mice provide a model for the role of BCL3 in B-cell neoplasia. The phenotype of BCL3 transgenic mice reveals that transgene expression in lymphoid cells leads to apparently normal animals and unimpaired development of the immune system. This has enabled us to study the cellular eects of BCL3 transgene expression on the immune system and particularly in the B-cell population. Our studies have show there to be a consistent phenotype in BCL3 transgenic mice that is characterized primarily by a generalized accumulation of mature B cells in bone marrow, lymph nodes, and peritoneal cavity. All ®ve transgenic lines studied showed a similar degree of phenotype expression although only two were examined in detail. These changes have been observed in mice as early as 5 weeks old.
While many of the phenotypic alterations showed relatively little variation among transgenic animals, there was considerable variability in spleen weights among transgenic animals that correlated with levels of anti-DNA IgG1 and with mesenteric lymphadenopathy. Although the animals have been maintained in a speci®c pathogen-free facility, chance encounters with environmental antigens or nonpathogenic bacteria or viruses may play a role in this variability. The eects of this variable were minimized by comparing transgenic animals with control nontransgenic littermates that likely had similar antigenic exposures.
The phenotypic consequences of BCL3 expression are consistent with its being one step in the multistep development of B-cell neoplasia although it is not in itself sucient for B-cell transformation. The BCL3 transgene appears to lead to increased accumulation of both CD5-positive B-lymphocytes (B1-a cells) and the more abundant B2 cells. This is consistent with the occurrence of the t(14;19) not only in CLL but also in de novo B-cell lymphoma of various morphological subtypes.
Interestingly, transgene expression in T cells does not lead to similar changes in this population. It is possible that the phenotype observed is dependent on cooperative eects between transgenic T and B cells as the transgene is expressed in both populations in our animals. Testing this hypothesis will require further work to generate mice that express the Em-BCL3 transgene only in B cells. However, the simplest explanation of the phenotype would be an eect that is intrinsic to the B cell.
Little is known of the physiologic role of BCL3 although prior work has shown that, during B-cell ontogeny, BCL3 is most highly expressed in mature B cells and plasma cells, and that it can function as an immediate early response gene in response to both Tand B-cell mitogens. Several lines of evidence from our experiments indicate that Em-BCL3 transgenic mice possess a hyperresponsive humoral immunity.
Firstly, we have found that Em-BCL3 transgenic B cells show an increased sensitivity to BCR cross-linking as judged by proliferative responses and upregulation of CD86. These results support the notion that BCL3 may be involved in the regulation of genes involved in the mitogenic response to BCR cross-linking, specifically the surface expression of CD86.
Further evidence for a hyperresponsive humoral immunity is the increased incidence of autoantibodies in transgenic animals. Levels of antibody positively correlated with spleen weight, suggesting that an autoimmune state may account for at least part of the phenotype of Em-BCL3 mice. In this respect the ®nding of increased CD86 expression suggests a possible mechanism by which the anti-dsDNA antibodies arise. CD86 has been implicated in the development of several autoimmune conditions including the anti-dsDNA autoantibodies in the lupus-prone NZB/W F1 mouse model. The administration of anti-CD86 to such mice results in the complete inhibition of anti-dsDNA of IgG1 and IgG2b subtypes, while only partially suppressing that of IgG2a (Nakajima et al., 1995) , presumably preventing the necessary costimulation of T helper [Th] cells by CD86-expressing B cells. In Em-BCL3 animals the initial antigenic stimulus may be from the chance encounter with an environmental antigen that leads to the dysregulated expression of CD86 on B Figure 6 Natural logarithm of anti-dsDNA (IgG2a) against spleen weight among control and transgenic animals. For transgenic animals the correlation between these two variables is 0.54, while for control animals the correlation is 70.35. PC denotes the OD of pooled sera from SNF1 mice included as a positive control BCL3 transgenic mice develop a lymphoproliferative disorder S Tiong Ong et al cells, the subsequent activation of Th cells, and thence the generation of the autoimmune phenomenon.
A third piece of evidence for an activated immune state is the ®nding, in unstimulated animals, of a consistent threefold increase in the number of GC cells in lymph nodes independent of lymph node size. While this ®nding may re¯ect a generalized immune hyperresponsiveness it may also reveal a speci®c eect of BCL3-overexpression on GC formation. Evidence that BCL3 plays a role in GC formation comes from targeted gene disruption studies: mice lacking BCL3 show a complete failure in GC formation when challenged with T celldependent antigen (Franzoso et al., 1997; Schwarz et al., 1997) . These two observations argue that the upregulation of BCL3 may be a requirement for GC formation.
Multiple factors are important in the development of GC's, and key cellular components include not only B cells but also antigen-speci®c Th cells (Fuller et al., 1993) and follicular dendritic cells, which serve as antigen-presenting cells for B lymphocytes (Mandel et al., 1980; Schriever and Nadler, 1992) . Interactions between several cell surface receptors are considered necessary for both the proliferative and dierentiative aspects of GC formation. These include interactions between CD40 on B cells and CD40L found on activated Th cells (Foy et al., 1994; Renshaw et al., 1994) , and CD28/CTLA4 on Th cells and CD80 and CD86 (B7-1 and -2) found on activated B cells (Linsley et al., 1992) .
Em-BCL3 mice also show statistically signi®cant abnormalities in their serum immunoglobulin levels, most notably a decrease in IgM and IgG3 levels but an increase in IgG1 and IgA. Examination of B1 B cells or IgA surface-positive B cells in the peritoneal cavity and Peyer's patches respectively has not revealed any quantitative changes that may account for the dierences in serum immunoglobulin levels. Besides re¯ecting an overall increase in B cell responsiveness, these abnormalities may result from an eect of BCL3 on immunoglobulin production, isotype switching, or immunoglobulin secretion.
Recent studies have demonstrated p50/NF-kB binding sites in the murine switch (S) g3, Sg1, and Sg2b regions (Kenter et al., 1993) and in the germline promoters of the Ig3 (Gerondakis et al., 1991) and Ig1 (Lin and Stavnezer, 1996) genes, suggesting possible mechanisms by which Ig levels may be in¯uenced by alterations in NF-kB/IkB family members. Furthermore, B cells from p50 knockout mice have selective defects in germline constant region transcription and Ig class switching in response to various stimuli (Snapper et al., 1996) . Speci®cally, p50 7/7 B cells have a marked defect in maturation to IgM secretion despite normal levels of proliferation, and are defective in IgG3, IgE, and IgA class switching but can undergo substantial switching to IgG1. It remains to be determined whether BCL3's apparent eect on class switching is mechanistically related to that of p50.
In summary, our studies show that BCL3 transgene expression leads to a generalized accumulation of mature B cells, which is fully consistent with the pathogenetic role of the t(14;19) translocation in B cell malignancies. In addition, the hyperresponsive nature of the Em-BCL3 B cells oers a possible biological explanation as to why patients with the t(14;19) have a worse prognosis than those without it.
From in vitro studies, it is apparent that BCL3 has the potential to aect many components of the immune system via kB-regulated genes. Indeed, the existence of so many potential`targets' makes it dicult to de®ne its speci®c biological roles. The phenotype and functional eects of BCL3 transgene described here clearly demonstrate an important role in the humoral arm of the immune system and are a mirror image of the eects of disruption of the gene. It follows that at least some of the kB-regulated genes involved in the generation of a humoral response are speci®cally aected by BCL3.
Orchestration of the immune response requires convergence of multiple signals. It is likely that speci®c stimuli required for B cell activation induce BCL3 expression. If inappropriate expression circumvents the requirement for such stimuli, activation may occur under circumstances which are normally insufficient. The Em-BCL3 transgenic mouse oers a model in which to study further BCL3's role in normal immune responses and in B-cell neoplasia.
Materials and methods
Construction of transgene
The transgenic construct is a derivative of the OVEC-1 vector (Westin et al., 1987) , which contributes a partial rabbit b-globin sequence including an intron and polyadenylation site. The murine Igh Em enhancer (a 685 bp XbaI ± EcoRI fragment) was ligated upstream of a short murine V H promoter sequence (780 ± +40) (Gillies et al., 1983; Grosschedl and Baltimore, 1985) , which was blunt end ligated to human BCL3 sequences extending just beyond the coding sequences, isolated from the cDNA by digestion with BglII and partial digestion with SstII.
Generation and maintenance of transgenic mice
Transgenic animals were generated from C3H Hen Cr MTVmice from the Frederick Cancer Research Facility (Frederick, MD) by injection of the transgene into fertilized eggs, which were then transplanted into pseudopregnant females. Founder animals were identi®ed by Southern hybridization of DNA from tail clippings, using full-length human cDNA as a probe. Eight mg of genomic DNA was completely digested with SstI and separated on a 0.8% agarose gel at 50 V for 12 h. The DNA was then denatured, neutralized, and transferred to a nylon membrane and cross-linked by U.V. light. The Southern blots were then hybridized at 428C overnight with 32 P-labeled full-length human BCL3 cDNA, and subjected to autoradiography after washing according to standard conditions (McKeithan et al., 1997) . Founders were identi®ed by the presence of bands of the expected size.
Of 26 pups, eight were transgenic. From these founders, ®ve lines (#6, 8, 13, 18, and 25) were bred, and two lines (#8 and #13) were examined in detail. Subsequent identi®cation relied on PCR analysis of toe clippings using the following primer pair: sense, 5'-CTCCAGGAGGCAGCTGAG-3', antisense, GGTCCATGGTGATACAAGGG, giving an ampli®ed product of 176 bp. The PCR conditions that yielded an optimal signal were 30 cycles with 60 s at 948C for DNA denaturation, 75 s at 528C for primer annealing, 75 s at 728C for extension, with a ®nal extension time of 7 min at 728C. The PCR mix consisted of 0.5 U Taq polymerase, 200 mM of each deoxyribonucleotide triphosphate, 1.0 mM MgCl 2 , 10 mM Tris-HCl, 50 mM KCl at pH 8.3 in a volume of 50 ml. Throughout these experiments mice were maintained in speci®c pathogen-free facilities and were handled according to strict animal care guidelines. Periodic tests of the colony for murine parvovirus, Helicobacter hepaticus, and other pathogens were persistently negative in animals used in experiments.
RNA extraction and RT ± PCR
RNA was extracted from spleen, lymph node, and thymus, and puri®ed splenic B cells using the TRIZOL LS system (Gibco/BRL, Gaithersburg, MD) and RT ± PCR performed on cDNA generated from total RNA using the Superscript II system (Gibco/BRL) and oligo-dT priming. PCR was performed on the cDNA product employing primers that spanned the intron in the transgene: sense, 5'-CTCC-AGGAGGCAGCTGAG-3'; antisense, TCTGATAGG-CAGCCTGCAC, giving a 133 bp product. The PCR product was run on a 2.5% agarose gel and stained with ethidium bromide. Primers for the housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (Hprt) were: sense, 5'-GTTGGATACAGGCCAGAC-TTTGTTG-3'; antisense, GAGGGTAGGCTGGCCTA-TGGCT, giving a 352 bp product (Johnson et al., 1988) .
Histological analysis
Freshly dissected tissue from thymus, spleen, mesenteric and inguinal lymph nodes, skin, sternum, small bowel, and liver were ®xed in 10% formalin solution. Fixed specimens were embedded in paran, sectioned, and stained in hematoxylin and eosin.
Flow cytometry
Single cell suspensions were made from various tissues including thymus, spleen, lymph node, and Peyer's patches. Bone marrow cells were harvested from femur and tibia, bȳ ushing the marrow cavities with PBS using 21G and 25G needles. Peritoneal cells were obtained by injecting 10 ml of PBS into the peritoneum, massaging the abdomen, and withdrawing the¯uid. Cells were initially incubated for 10 min with rat IgG2b anti-FcgRII (2.4G2) to prevent nonspeci®c binding of¯uorochrome-conjugated antibody. 3 H]thymidine uptake was measured on a beta emission scintillation counter using Microscint scintillation¯uid (Packard, Meriden, CT). Triplicate or sextuplicate values were averaged. F(ab') 2 goat anti-murine m (Jackson ImmunoResearch Laboratories, West Grove, PA) was also used at 10 mg/ml to stimulate both whole spleen cells and T-depleted cell population and proliferation assessed using [ 3 H]thymidine incorporation.
To assess induction of CD86, 1610 6 splenocytes were cultured with F(ab') 2 goat anti-murine m at 0. 1.5 and 5 mg/ml in a volume of 200 ml in round-bottomed 96 well plates. After 24 h, cells were harvested, washed and simultaneously stained with B220-PE and CD86-FITC, and analysed by¯ow cytometry.
Cell survival assays employed the use of the dye 7-aminoactinomycin D (7-AAD) (Sigma Chemical Co., St Louis, MO), which crosses the cell membranes of apoptotic cells and binds to DNA (Schmid et al., 1994) . Cells were initially incubated for 10 min with rat IgG2b anti-FcgRII (2.4G2) to prevent non-speci®c binding of¯uorochrome-conjugated antibody. Cells were surface stained as described above and then suspended in 500 ml PBS/0.001% azide containing 20 mg/ml of 7-AAD at 48C for 20 min, and then analysed by¯ow cytometry.
B220-positive cell selection
B cells were isolated from spleen suspension using a twostep procedure. Firstly, T cells were lysed by incubation with anti-Thy1.2 (AT83.A) antibody and rabbit complement (PelFreez, Milwaukee, WI) at 378C for 45 min. The cells were then spun down and washed, and lymphocytes were fractionated by Ficoll-Paque gradient (Pharmacia Biotech, Piscataway, NJ). The remaining cells were then labeled with B220-coated magnetic beads using the MiniMACS system (Miltenyi Biotec, Auburn, CA) and selected for B220-positivity. Cells obtained by this method were consistently greater than 96% B220 positive as determined by¯ow cytometry.
Measurement of serum immunoglobulin
Mice were bled from the retro-orbital sinus or terminally via cardiac punctures. Serum immunoglobulin levels were determined by isotype-speci®c enzyme-linked immunosorbent assay (ELISA). Ninety-six well¯at-bottomed plates (Nunc, Roskilde, Denmark) were coated with goat antimouse IgG(H+L) (Jackson ImmunoResearch Laboratories) at 0.5 mg/ml as the capture antibody and left overnight at 48C. The plates were then blocked with 1% BSA in PBS and left at room temperature for 1 h. After washing four times with PBS and 0.1% TWEEN 20, serial dilutions of serum was added and kept overnight at 48C. After washing four times, alkaline phosphatase-conjugated rabbit anit-mouse IgG1, IgG2a, IgG2b, IgG3, IgA (Zymed, San Francisco, CA) or goat anti-mouse IgM (Jackson ImmunoResearch Laboratories) were used as detection antibodies. The plates were then washed six times and pnitrophenyl phosphate (Southern Biotechnology Associates) in 0.05 M diethanolamine buer was added.
The concentration of individual immunoglobulins was determined from standard curves of ELISA optical densities and isotype-speci®c antibodies of known concentration (Southern Biotechnologies Associates). For measurement of IgE, an anti-mouse capture antibody (R35-72, PharMingen) was used with a detection antibody consisting of biotinylated anti-mouse IgE (R35-92, PharMingen). Standard curves were obtained with a puri®ed mouse IgE standard (IgE-3, PharMingen).
Levels of antibody speci®c for double-stranded (ds) DNA were also measured by ELISA (Madaio et al., 1984) . For the detection of dsDNA-speci®c antibody 96-well plates were coated with poly-L-lysine (50 mg/ml) (Sigma Chemical Co.) for 1 h at room temperature, and then with human placental DNA and left overnight at 48C, and ®nally with poly-Lglutamate (50 mg/ml) (Sigma Chemical Co.) for 1 h at room temperature and washed. The plates were then blocked with PBS and 1% BSA for 2 h at room temperature. Serial dilutions (1/50 and 1/500) of serum were incubated overnight at 48C and washed four times. Pooled serum obtained from several (NZB6SWR)F1 (SNF1) mice (Datta et al., 1997) was used as a positive control. Alkaline phosphatase-conjugated goat anti-mouse Ig (IgG2a, IgG2b, IgM, IgG (H+L)) was added to each well and incubated for 4 h at 48C. After the plates were washed six times, bound alkaline phosphatase was detected by the addition of pnitrophenyl phosphate. The reaction was stopped and optical densities were read at 405 nm.
Immunohistochemistry
Four mm sections of each sample were mounted onto superfrost plus slides (Fisher Scienti®c, Pittsburgh, PA), baked at 608C for 1 h, cleared in xylene, and hydrated through a descending alcohol series to distilled water. For B220 and IgG staining, the slides were pretreated using microwave antigen retrieval. The hydrated tissue sections were placed in a coplin jar containing 0.01 M citrate buer, pH 7.0 inside a Samsung 1.5 cubic feet, 900 W microwave. The tissue sections were heated for 2 min at full power, followed by 13 min at 20% power. The heated sections were allowed to cool for 15 min and washed in running water. For IgM staining, the slides were treated with Protease 1 (Ventana Medical Systems, Tucson, AZ) for 16 min at 378C. After pretreatment, endogenous peroxidase activity was blocked by treating the sections with 3% hydrogen peroxide in methanol for 20 min.
Two tissue sections from each case were then incubated overnight at 48C with a mouse monoclonal antibody generated against B220 (01121D, PharMingen), mouse IgM (02082D, PharMingen), or mouse IgG (Ventana Medical Systems). One slide from each sample was treated in a similar fashion using normal mouse serum immunoglobulin. The immunohistochemical staining was performed on a Ventana Gen II system (Ventana Medical Systems), which utilizes an indirect streptavidin biotin system conjugated with horseradish peroxidase for detecting the immunocomplex and a diaminobenzidine as a substrate for localization. The immunostained sections were counterstained with hematoxylin, dehydrated through an ascending alcohol series, cleared and coverslipped. A positive reaction was indicated by the accumulation of a brown reaction product at the cell surface (B220) or cytoplasm of the cell (IgG and IgM).
Statistical methods
Linear regression models predicting log spleen weight and body weight were ®t to the data, using litter, sex, and mouse type (control vs transgenic) as covariates. The decision to transform spleen weight was based on the observation that the variability in spleen weight increases with the mean; the decision to use a logarithmic transformation was con®rmed using the Box-Cox method. Note that since all animals in a litter were sacri®ced on the same day, including litter as a covariate implies controlling for age. Residual plots were used to con®rm the adequacy of the models.
In the case of ant-dsDNA Ab levels, a plot of the values separately by mouse type revealed one particular large value in each group. Thus, in order to limit the in¯uence of these two observations, the medians were computed for each group and compared. In addition, Wilcoxon's rank-sum test was used to test the null hypothesis that the underlying distributions for the two groups is the same.
The remaining data were analysed using linear regression models including mouse type, sex, and age (linear eect) as covariates. In addition, for those assays that were performed on two dierent days, day of measurement was also included as a two-level covariate. All dependent variables were ®rst transformed using natural logarithms in order to stabilize the variance. P-values and con®dence intervals are based on the appropriate t-distribution.
